(0.10%) 5 244.25 points
(0.12%) 39 585 points
(0.08%) 18 228 points
(0.68%) $79.80
(1.43%) $2.33
(0.85%) $2 360.30
(0.93%) $28.63
(0.34%) $994.20
(0.09%) $0.928
(-0.10%) $10.86
(0.07%) $0.799
(0.17%) $92.70
1.72% $ 1.180
Live Chart Being Loaded With Signals
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally...
Stats | |
---|---|
Dzisiejszy wolumen | 705 131 |
Średni wolumen | 969 356 |
Kapitalizacja rynkowa | 222.78M |
EPS | $0 ( 2024-05-09 ) |
Następna data zysków | ( $-0.0400 ) 2024-06-11 |
Last Dividend | $0.0800 ( 2003-12-15 ) |
Next Dividend | $0 ( N/A ) |
P/E | -9.83 |
ATR14 | $0.00500 (0.43%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-07 | Culley Brian M | Buy | 1 900 000 | Employee Stock Option (Right to Buy) |
2024-03-07 | Samuel George A. Iii | Buy | 650 000 | Employee Stock Option (Right to Buy) |
2024-03-07 | Howe Jill Ann | Buy | 650 000 | Employee Stock Option (Right to Buy) |
2024-02-11 | Samuel George A. Iii | Sell | 6 076 | Restricted Stock Units |
2024-02-11 | Samuel George A. Iii | Buy | 6 076 | Common Shares, no par value |
INSIDER POWER |
---|
98.19 |
Last 93 transactions |
Buy: 20 710 358 | Sell: 1 476 683 |
Wolumen Korelacja
Lineage Cell Therapeutics Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Lineage Cell Therapeutics Korelacja - Waluta/Towar
Lineage Cell Therapeutics Finanse
Annual | 2023 |
Przychody: | $8.95M |
Zysk brutto: | $7.58M (84.76 %) |
EPS: | $-0.120 |
FY | 2023 |
Przychody: | $8.95M |
Zysk brutto: | $7.58M (84.76 %) |
EPS: | $-0.120 |
FY | 2022 |
Przychody: | $14.70M |
Zysk brutto: | $13.98M (95.05 %) |
EPS: | $-0.160 |
FY | 2021 |
Przychody: | $3.90M |
Zysk brutto: | $2.47M (63.40 %) |
EPS: | $-0.260 |
Financial Reports:
No articles found.
Lineage Cell Therapeutics Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.0800 | 2003-12-15 |
Last Dividend | $0.0800 | 2003-12-15 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $0.0800 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.01 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
WTV | Ex Dividend Junior | 2023-06-26 | Quarterly | 0 | 0.00% | |
CET | Ex Dividend Knight | 2023-06-09 | Semi-Annually | 0 | 0.00% | |
FRD | Ex Dividend Knight | 2023-10-19 | Quarterly | 0 | 0.00% | |
NEN | Ex Dividend Knight | 2023-09-14 | Quarterly | 0 | 0.00% | |
SVOL | Ex Dividend Junior | 2023-08-28 | Monthly | 0 | 0.00% | |
BITO | Ex Dividend Knight | 2023-09-01 | Bi-Monthly | 0 | 0.00% | |
ESP | Ex Dividend Knight | 2023-06-22 | Semi-Annually | 0 | 0.00% | |
MMCA | Ex Dividend Junior | 2023-09-01 | Bi-Monthly | 0 | 0.00% | |
RIET | Ex Dividend Junior | 2023-09-12 | Monthly | 0 | 0.00% | |
AE | Ex Dividend Knight | 2023-09-07 | Quarterly | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -2.41 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.213 | 1.200 | -7.10 | -8.52 | [0 - 0.3] |
returnOnEquityTTM | -0.313 | 1.500 | -4.59 | -6.89 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 2.14 | 0.800 | 4.30 | 3.44 | [1 - 3] |
quickRatioTTM | 2.02 | 0.800 | 2.84 | 2.27 | [0.8 - 2.5] |
cashRatioTTM | 1.973 | 1.500 | 0.148 | 0.222 | [0.2 - 2] |
debtRatioTTM | 0.0292 | -1.500 | 9.51 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 56.86 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.165 | 2.00 | -0.0551 | -0.110 | [0 - 30] |
freeCashFlowPerShareTTM | -0.169 | 2.00 | -0.0847 | -0.169 | [0 - 20] |
debtEquityRatioTTM | 0.0465 | -1.500 | 9.81 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.905 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | -2.77 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -9.68 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.0885 | 0.800 | -2.74 | -2.19 | [0.5 - 2] |
Total Score | -0.295 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -9.31 | 1.000 | -1.041 | 0 | [1 - 100] |
returnOnEquityTTM | -0.313 | 2.50 | -2.95 | -6.89 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.169 | 2.00 | -0.0564 | -0.169 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.165 | 2.00 | -0.0551 | -0.110 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.0603 | 1.500 | -2.93 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -3.19 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -2.30 |
Lineage Cell Therapeutics
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers Renevia, a facial aesthetics product. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej